Holen Sie sich die Stockscreener-App
114.80
9.06%
9.54
Vorhandelsmarkt:
116.70
1.90
+1.66%
Veradermics Inc Aktie (MANE) Neueste Nachrichten
Suvretta funds boost Veradermics (MANE) position with pre-funded warrants - Stock Titan
Longitude group discloses 4.65M Veradermics (MANE) shares owned - Stock Titan
Seven Fleet (NASDAQ: MANE) files 13D on Veradermics 0.2% equity stake - Stock Titan
Seven Fleet discloses 80,000 Veradermics (MANE) shares in Form 3 - Stock Titan
Experimental hair loss pill just cleared a major hurdle — when it could hit shelves - New York Post
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill - Yahoo Finance
The week in pharma: action, reaction and insight – week to May 1, 2026 - The Pharma Letter
Veradermics, Inc. Securities Purchase Agreement and Pre-Funded Warrant Details (May 2026) - Minichart
Veradermics Incorporated (MANE) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
[8-K] Veradermics, Inc Reports Material Event - Stock Titan
Looking to Regrow Hair? New Options Are on the Horizon - WSJ
Veradermics’ stock grows on pivotal hair loss win - MSN
Is It Too Late To Consider Veradermics (MANE) After A 162% Year To Date Surge? - simplywall.st
Veradermics (MANE) sells 3.84M shares at $100; $300k-warrant PIPE - Stock Titan
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 - Insider Monkey
[EFFECT] Veradermics, Inc SEC Filing - Stock Titan
A Look At Veradermics (MANE) Valuation After Breakthrough Phase 2/3 Results For Oral Hair Loss Drug - simplywall.st
Veradermics prices $384M stock offering at $100 per share By Investing.com - Investing.com India
Veradermics Announces Pricing of Upsized Public Offering and Private Placement - The National Law Review
Veradermics prices $384M stock offering at $100 per share - Investing.com UK
Veradermics: Closing of Public Offering Isn't Contingent on Private Placement >MANE - Moomoo
Hair-loss drug developer Veradermics prices $384.4M stock sale - Stock Titan
Veradermics announces pricing of upsized public offering and private placement - marketscreener.com
Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01 - Sahm
Veradermics (MANE) price target increased by 15.32% to 92.14 - MSN
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains - Yahoo Finance
Veradermics announces launch of public offering - MSN
Technical Analysis of Veradermics, Incorporated (NYSE:MANE) - TradingView
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings - Sahm
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis (NYSE:MANE) - Seeking Alpha
New Oral Drug Shows Success in Reversing Hair Loss - inc.com
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $120 - Moomoo
Veradermics launches public offering of 3.35 million shares By Investing.com - Investing.com South Africa
Veradermics launches public offering of 3.35 million shares - Investing.com Australia
Veradermics announces offering of 3.35M shares of common stock - TipRanks
Veradermics Announces Launch of Public Offering - WFMZ.com
Veradermics (NYSE: MANE) reports $390.8M preliminary cash and securities - Stock Titan
VDPHL01 hair-loss data and $212.9M capital raise for Veradermics (NYSE: MANE) - Stock Titan
MANE event: Veradermics beats expectations in pattern hair loss trial - BioWorld News
MANE Stock Explodes Higher As Traders Pile Into Breakout - timothysykes.com
How This Biotech Is Taking A Page Out Of Rogaine's Playbook - Investor's Business Daily
MANE Stock Rockets On Breakout As Traders Pile In - StocksToTrade
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals - TechStock²
Veradermics price target raised to $120 from $85 at Citi - TipRanks
Veradermics (MANE) Stock Rockets On Heavy Momentum - timothysykes.com
Veradermics hair loss pill passes late-stage clinical trial - Yahoo Finance
MANE Stock Rockets On Volatile Breakout Move - StocksToTrade
Veradermics soars on positive data for baldness treatment - BioPharma Dive
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):